Guangdong, China and Bagswaard, Denmark –
Media Outreach Newswire – March 24, 2025 – Today, the United Laboratories are limited to international holdings (TUL) and Novo Nordisk A / S (Novo Nordisk), Novo Nordisk and Tulun, United Bio-Technology (Hengqin) Co., Ltd. (combined biotechnology), GLP-1 for the exclusive license agreement for the GLP-1. Gypsia and glucagon in early staged clinical development for treatment, 2 diabetes and other diseases.
Under the license agreement, Novo Nordisk will acquire Exclusive rights (Chinese Matu, Hong Kong, Macau, Macau and Taiwan) to develop, produce and commercialize UVT251. United biotechnology will maintain UVT251 rights in the Chinese Mainland, Hong Kong, Macau and Taiwan. United Biotechnology, $ 200 million and Novo Nordisk potential phase payments to $ 1.8 billion, as well as the potential phase of potential royalties in net sales outside China, Hong Kong, Macau and Taiwan.
“In addition to developing a variety of need for development, the development of various needles, Novo Nordige, including Novo Nordisk, obesity, 2 types of diabetes, as well as GLP-1 and GIPs, including GLP-1 and GIPs, and the Development of Development in Novo Nordus.” We look forward to the best exploration of UVT251’s potential best features in cardiometabolic diseases. ”
United biotechnology is designed to evaluate more than one subcutaneous injections and phase of UVT251 in people with a randomized, double blind, placebo-controlled, double blind, placebo-controlled Phase 1B.
A total of 36 patients were registered in three different doses (1 mg, 1mg / 3mg, 1 mg / 3mg / 6mg). Each group accepted a dose-titreed method with an injecting injecting in a 24-week week week.
UVT251’s security profile was in accordance with increased-based treatments. The most common negative events were the gastrointestinal and the vast majority were mildly moderate. In the highest dose group, the average weight of people who completed the court decreased by 15.1%, the average weight of people in the Plasebo group increased by 1.5%.
“It is pleased to announce our exclusive license agreement with UVO Nordisk. As a leading global Biofarbatika, Novo Nordisk is a strong position in the treatment of chronic diseases,” he said. “TULS is eager to strengthen the participation of chronic diseases, including endocrine and metabolic disorders, including endocrine and metabolic disorders.
This cooperation represents a basic stage in the continuing efforts to create a global strategic entity and demonstrate the faithfulness of innovation. TUL will continue to develop high quality and sustainable development in scientific innovation and develop a world competitive framework for production, intermediate / interim and trade.
The closure of this transaction is subject to the applicable regulation and other customs.
Hashtag: #Tul
The issuer is only responsible for the content of this announcement.
